<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 21 - FOOD AND DRUGS</title></head><body>
<span style="font-weight:bold;font-size:12pt;">21 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 1995 Edition</span><br/>
<span style="font-size:10pt">Title 21 - FOOD AND DRUGS</span><br/>
<span style="font-size:10pt">CHAPTER 8 - NARCOTIC FARMS</span><br/>
<span style="font-size:10pt">10</span><br/>
<span style="font-size:10pt">Front Matter</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- field-start:notes -->
<!-- field-start:miscellaneous-note -->
<h4 class="note-head">Part A&mdash;Drugs and Devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">351.</div><div class="two-column-analysis-style-content-right">Adulterated drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Poisonous, insanitary, etc., ingredients; adequate controls in manufacture.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Strength, quality, or purity differing from official compendium.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Misrepresentation of strength, etc., where drug is unrecognized in compendium.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Mixture with or substitution of another substance.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Devices not in conformity with performance standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Certain class III devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Banned devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Manufacture, packing, storage, or installation of device not in conformity with applicable requirements or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Failure to comply with requirements under which device was exempted for investigational use.</div></div>
<div><div class="two-column-analysis-style-content-left">352.</div><div class="two-column-analysis-style-content-right">Misbranded drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">False or misleading label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Package form; contents of label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Prominence of information on label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Habit forming substances.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Designation of drugs or devices by established names.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Directions for use and warnings on label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Representations as recognized drug; packing and labeling; inconsistent requirements for designation of drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Deteriorative drugs; packing and labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Drug; misleading container; imitation; offer for sale under another name.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Health-endangering when used as prescribed.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Insulin not properly certified.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l)</em></div><div class="two-column-analysis-style-content-subitem-right">Antibiotic drugs improperly certified.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Color additives; packing and labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Prescription drug advertisements: established name; quantitative formula; side effects, contraindications, and effectiveness; prior approval; false advertising; labeling; construction of the Convention on Psychotropic Substances.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o)</em></div><div class="two-column-analysis-style-content-subitem-right">Drugs or devices from nonregistered establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(p)</div><div class="two-column-analysis-style-content-subitem-right">Packaging or labeling of drugs in violation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(q)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices using false or misleading advertising or used in violation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(r)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices not carrying requisite accompanying statements in advertisements and other descriptive printed matter.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(s)</div><div class="two-column-analysis-style-content-subitem-right">Devices subject to performance standards not bearing requisite labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(t)</div><div class="two-column-analysis-style-content-subitem-right">Devices for which there has been a failure or refusal to give required notification or to furnish required material or information.</div></div>
<div><div class="two-column-analysis-style-content-left">353.</div><div class="two-column-analysis-style-content-right">Exemptions and consideration for certain drugs, devices, and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Regulations for goods to be processed, labeled, or repacked elsewhere.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Sales restrictions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Distribution of drug samples.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Wholesale distributors; guidelines for licensing; definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Veterinary prescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Regulation of combination products.</div></div>
<div><div class="two-column-analysis-style-content-left">354.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">355.</div><div class="two-column-analysis-style-content-right">New drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Necessity of effective approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Filing application; contents.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Grounds for refusing application; approval of application; &ldquo;substantial evidence&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to public health.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Revocation of order refusing, withdrawing or suspending approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Appeal from order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Exemptions of drugs for research; discretionary and mandatory conditions; direct reports to Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Abbreviated new drug applications.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Records and reports; required information; regulations and orders; access to records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l)</em></div><div class="two-column-analysis-style-content-subitem-right">Public disclosure of safety and effectiveness data.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">&ldquo;Patent&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-left">356.</div><div class="two-column-analysis-style-content-right">Certification of drugs containing insulin.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Standards for certification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Tests or methods of assay; revision.</div></div>
<div><div class="two-column-analysis-style-content-left">357.</div><div class="two-column-analysis-style-content-right">Certification of drugs containing penicillin, streptomycin, chlortetracycline, chloramphenicol, bacitracin, or any other antibiotic drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Regulations prescribed by Secretary; release prior to certification; &ldquo;antibiotic drug&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Provisions of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Exemption of drugs not involving safety and efficacy of use; considerations; certification after exemption; labeling and advertising claims.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Exemption of drugs stored, processed, and labeled at plants other than manufacturer's, used in manufacture of other drugs or for investigational purposes; discretionary and mandatory conditions; direct reports to Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Exempted new drugs subject to section 355 of this title; request for certification of exempted drug; determination of compliance with sections 351(b) and 352(g) of this title.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Filing of petitions; contents; notice; answer; public hearing; orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Records and reports; professional ethics and interests of patients; examination of data; access to records.<!-- PDFPage:45 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Issuance of regulations; conditions; amendment or repeal of regulations; effective date; procedure; lack of substantial evidence.</div></div>
<div><div class="two-column-analysis-style-content-left">358.</div><div class="two-column-analysis-style-content-right">Authority to designate official names.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Necessity or desirability; use in official compendiums; infringement of trademarks.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Review of names in official compendiums.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Determinations of complexity, usefulness, multiplicity, or lack of name; designation by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Revised official names; compilation, publication, and public distribution of listings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Request by compiler of official compendium for designation of name.</div></div>
<div><div class="two-column-analysis-style-content-left">359.</div><div class="two-column-analysis-style-content-right">Nonapplicability of subchapter to cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">360.</div><div class="two-column-analysis-style-content-right">Registration of producers of drugs or devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Annual registration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">New producers.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Additional establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Registration number; uniform system for identification of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Availability of registrations for inspection.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Exclusions from application of section.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Inspection of premises.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Foreign establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Filing of lists of drugs and devices manufactured, prepared, propagated and compounded by registrants; statements; accompanying disclosures.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Report preceding introduction of devices into interstate commerce.</div></div>
<div><div class="two-column-analysis-style-content-left">360a.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">360b.</div><div class="two-column-analysis-style-content-right">New animal drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Unsafe new animal drugs and animal feed containing such drugs; conditions of safety; exemption of drugs for research.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Filing application for uses of new animal drug; contents; patent information; abbreviated application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order; abbreviated applications; withdrawal periods; effective date of approval; relationship to other applications; withdrawal or suspension of approval; bioequivalence; filing of additional patent information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Grounds for refusing application; approval of application; factors; &ldquo;substantial evidence&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to health of man or animals.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Revocation of order refusing, withdrawing or suspending approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Appeal from order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Publication in Federal Register; effective date and revocation or suspension of regulation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Exemption of drugs for research; discretionary and mandatory conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Food containing new animal drug considered unadulterated while approval of application for such drug is effective.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l)</em></div><div class="two-column-analysis-style-content-subitem-right">Records and reports; required information; regulations and orders; examination of data; access to records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)(1)</div><div class="two-column-analysis-style-content-subitem-right">Filing application for uses of animal feed containing new animal drug; contents.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(2)</div><div class="two-column-analysis-style-content-subitem-right">Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(3)</div><div class="two-column-analysis-style-content-subitem-right">Grounds for refusing application; approval of application; approval effective during existence of subsection (i) regulation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(4)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to health of man or animals.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(5)</div><div class="two-column-analysis-style-content-subitem-right">Records and reports; regulations and orders; access to records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Abbreviated applications for new animal drugs; contents, filing, etc.; lists of approved drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o)</em></div><div class="two-column-analysis-style-content-subitem-right">&ldquo;Patent&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(p)</div><div class="two-column-analysis-style-content-subitem-right">Safety and effectiveness data.</div></div>
<div><div class="two-column-analysis-style-content-left">360c.</div><div class="two-column-analysis-style-content-right">Classification of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Classes of devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Classification panels.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Classification panel organization and operation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Panel recommendation; publication; priorities.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Classification changes.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Initial classification and reclassification of certain devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Substantial equivalence.</div></div>
<div><div class="two-column-analysis-style-content-left">360d.</div><div class="two-column-analysis-style-content-right">Performance standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Reasonable assurance of safe and effective performance; periodic evaluation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Establishment of a standard.</div></div>
<div><div class="two-column-analysis-style-content-left">360e.</div><div class="two-column-analysis-style-content-right">Premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General requirement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulation to require premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Application for premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Action on application for premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal and temporary suspension of approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Product development protocol.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Revision.</div></div>
<div><div class="two-column-analysis-style-content-left">360f.</div><div class="two-column-analysis-style-content-right">Banned devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Special effective date.</div></div>
<div><div class="two-column-analysis-style-content-left">360g.</div><div class="two-column-analysis-style-content-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Petition; record.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Additional data, views, and arguments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Standard for review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Finality of judgments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Remedies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Statement of reasons.</div></div>
<div><div class="two-column-analysis-style-content-left">360h.</div><div class="two-column-analysis-style-content-right">Notification and other remedies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Repair, replacement, or refund.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Reimbursement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Effect on other liability.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Recall authority.</div></div>
<div><div class="two-column-analysis-style-content-left">360i.</div><div class="two-column-analysis-style-content-right">Records and reports on devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">User reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Persons exempt.<!-- PDFPage:46 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Certification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Device tracking.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Reports of removals and corrections.</div></div>
<div><div class="two-column-analysis-style-content-left">360j.</div><div class="two-column-analysis-style-content-right">General provisions respecting control of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Custom devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Trade secrets.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Notices and findings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Good manufacturing practice requirements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Exemption for devices for investigational use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Release of information respecting safety and effectiveness.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Proceedings of advisory panels and committees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Traceability.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Research and development.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l)</em></div><div class="two-column-analysis-style-content-subitem-right">Transitional provisions for devices considered as new drugs or antibiotic drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Humanitarian device exemption.</div></div>
<div><div class="two-column-analysis-style-content-left">360k.</div><div class="two-column-analysis-style-content-right">State and local requirements respecting devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exempt requirements.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>l.</em></div><div class="two-column-analysis-style-content-right">Postmarket surveillance.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Surveillance approval.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Drugs for Rare Diseases or Conditions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360aa.</div><div class="two-column-analysis-style-content-right">Recommendations for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Request by sponsor; response by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-left">360bb.</div><div class="two-column-analysis-style-content-right">Designation of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Request by sponsor; preconditions; &ldquo;rare disease or condition&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Notification of discontinuance of drug or application as condition.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Notice to public.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-left">360cc.</div><div class="two-column-analysis-style-content-right">Protection for drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Exclusive approval, certification, or license.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exceptions.</div></div>
<div><div class="two-column-analysis-style-content-left">360dd.</div><div class="two-column-analysis-style-content-right">Open protocols for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ee.</div><div class="two-column-analysis-style-content-right">Grants and contracts for development of drugs for rare diseases and conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Electronic Product Radiation Control</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360hh.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ii.</div><div class="two-column-analysis-style-content-right">Program of control.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Powers of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Record keeping.</div></div>
<div><div class="two-column-analysis-style-content-left">360jj.</div><div class="two-column-analysis-style-content-right">Studies by the Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Report to Congress.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Participation of other Federal agencies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Organization of studies and participation.</div></div>
<div><div class="two-column-analysis-style-content-left">360kk.</div><div class="two-column-analysis-style-content-right">Performance standards for electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Promulgation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Administrative procedure.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Publication in Federal Register.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Availability of record.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Technical Electronic Product Radiation Safety Standards Committee.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Review and evaluation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Product certification.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>ll.</em></div><div class="two-column-analysis-style-content-right">Notification of defects in and repair or replacement of electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Notification; exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Method of notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Requisite elements of notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Copies to Secretary of communications by manufacturers to dealers or distributors regarding defects.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Notice from Secretary to manufacturer of defects or failure to comply with standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Correction of defects.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Effective date.</div></div>
<div><div class="two-column-analysis-style-content-left">360mm.</div><div class="two-column-analysis-style-content-right">Imports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Refusal of admission to noncomplying electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Bond.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Liability of owner or consignee for expenses connected with refusal of admission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Designation of agent for purposes of service.</div></div>
<div><div class="two-column-analysis-style-content-left">360nn.</div><div class="two-column-analysis-style-content-right">Inspection, records, and reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Inspection of premises.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Record keeping.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Disclosure of technical data.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Public nature of reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Trade secrets.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Information required to identify and locate first purchasers of electronic products.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>oo.</em></div><div class="two-column-analysis-style-content-right">Prohibited acts.</div></div>
<div><div class="two-column-analysis-style-content-left">360pp.</div><div class="two-column-analysis-style-content-right">Enforcement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Jurisdiction of courts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Penalties.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Venue; process.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Warnings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Compliance with regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Additional remedies.</div></div>
<div><div class="two-column-analysis-style-content-left">360qq.</div><div class="two-column-analysis-style-content-right">Annual report.</div></div>
<div><div class="two-column-analysis-style-content-left">360rr.</div><div class="two-column-analysis-style-content-right">Federal-State cooperation.</div></div>
<div><div class="two-column-analysis-style-content-left">360ss.</div><div class="two-column-analysis-style-content-right">State standards.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VI&mdash;COSMETICS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">361.</div><div class="two-column-analysis-style-content-right">Adulterated cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">362.</div><div class="two-column-analysis-style-content-right">Misbranded cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">363.</div><div class="two-column-analysis-style-content-right">Regulations making exemptions.</div></div>
<div><div class="two-column-analysis-style-content-left">364.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VII&mdash;GENERAL AUTHORITY</h4>
<h4 class="note-head">Part A&mdash;General Administrative Provisions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">371.</div><div class="two-column-analysis-style-content-right">Regulations and hearings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority to promulgate regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations for imports and exports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Conduct of hearings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Effectiveness of definitions and standards of identity.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Procedure for establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Review of order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Copies of records of hearings.</div></div>
<div><div class="two-column-analysis-style-content-left">372.</div><div class="two-column-analysis-style-content-right">Examinations and investigations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority to conduct.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Availability to owner of part of analysis samples.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Records of other departments and agencies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Information on patents for drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Powers of enforcement personnel.</div></div>
<div><div class="two-column-analysis-style-content-left">372a.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">373.</div><div class="two-column-analysis-style-content-right">Records of interstate shipment.</div></div>
<div><div class="two-column-analysis-style-content-left">374.</div><div class="two-column-analysis-style-content-right">Inspection.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Right of agents to enter; scope of inspection; notice; promptness; exclusions.<!-- PDFPage:47 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Written report to owner; copy to Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Receipt for samples taken.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Analysis of samples furnished owner.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Accessibility of records.</div></div>
<div><div class="two-column-analysis-style-content-left">375.</div><div class="two-column-analysis-style-content-right">Publicity.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Information regarding certain goods.</div></div>
<div><div class="two-column-analysis-style-content-left">376.</div><div class="two-column-analysis-style-content-right">Examination of sea food on request of packer; marking food with results; fees; penalties.</div></div>
<div><div class="two-column-analysis-style-content-left">377.</div><div class="two-column-analysis-style-content-right">Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.</div></div>
<div><div class="two-column-analysis-style-content-left">378.</div><div class="two-column-analysis-style-content-right">Advertising of foods.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Determination of misbranding; notification of Federal Trade Commission by Secretary; contents.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Action by Federal Trade Commission precluding action by Secretary; exception.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Secretary's determination of imminent hazard to health as suspending applicability of provisions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Coordination of action by Secretary with Federal Trade Commission.</div></div>
<div><div class="two-column-analysis-style-content-left">379.</div><div class="two-column-analysis-style-content-right">Confidential information.</div></div>
<div><div class="two-column-analysis-style-content-left">379a.</div><div class="two-column-analysis-style-content-right">Presumption of existence of jurisdiction.</div></div>
<div><div class="two-column-analysis-style-content-left">379b.</div><div class="two-column-analysis-style-content-right">Consolidated administrative and laboratory facility.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Awarding of contract.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Donations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
<div><div class="two-column-analysis-style-content-left">379c.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">379d.</div><div class="two-column-analysis-style-content-right">Automation of Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Colors</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379e.</div><div class="two-column-analysis-style-content-right">Listing and certification of color additives for foods, drugs, devices, and cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Unsafe color additives.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Listing of colors; regulations; issuance, amendment or repeal; referral to advisory committee; report and recommendations; appointment and compensation of advisory committee.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Certification of colors.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Procedure for issuance, amendment, or repeal of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Exemptions.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Fees</h4>
I74subpart 1&mdash;freedom of information fees<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379f.</div><div class="two-column-analysis-style-content-right">Recovery and retention of fees for freedom of information requests.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Use of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Waiver of fees.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 2&mdash;fees relating to drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379g.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379h.</div><div class="two-column-analysis-style-content-right">Authority to assess and use drug fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Types of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Fee amounts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Increases and adjustments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Fee waiver or reduction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Effect of failure to pay fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Assessment of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Crediting and availability of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Collection of unpaid fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Construction.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VIII&mdash;IMPORTS AND EXPORTS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">381.</div><div class="two-column-analysis-style-content-right">Imports and exports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Imports; list of registered foreign establishments; samples from unregistered foreign establishments; examination and refusal of admission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Disposition of refused articles.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Charges concerning refused articles.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Reimportation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Exports.</div></div>
<div><div class="two-column-analysis-style-content-left">382.</div><div class="two-column-analysis-style-content-right">Exports of certain unapproved products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Drugs intended for human or animal use which require approval or licensing.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Conditions for export; active pursuit of drug approval or licensing; application for export, contents, approval or disapproval; list of eligible countries for export; criteria for list change.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Report to Secretary by holder of approved application; events requiring report; annual report to Secretary on pursuit of approval of drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Export of drug under approved application prohibited.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Determination by Secretary of noncompliance, failure of active pursuit of drug approval, imminent hazard of drug to public health, or exportation of drug to noneligible country; notices and hearings; prohibition on exportation of drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Drugs used in prevention or treatment of tropical disease.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Reference to Secretary and holder of application.</div></div>
<div><div class="two-column-analysis-style-content-left">383.</div><div class="two-column-analysis-style-content-right">Office of International Relations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER IX&mdash;MISCELLANEOUS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">391.</div><div class="two-column-analysis-style-content-right">Separability clause.</div></div>
<div><div class="two-column-analysis-style-content-left">392.</div><div class="two-column-analysis-style-content-right">Exemption of meats and meat food products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Law determinative of exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Laws unaffected.</div></div>
<div><div class="two-column-analysis-style-content-left">393.</div><div class="two-column-analysis-style-content-right">Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Commissioner.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Technical and scientific review groups.</div></div>
<div><div class="two-column-analysis-style-content-left">394.</div><div class="two-column-analysis-style-content-right">Scientific review groups.</div></div>
<div><div class="two-column-analysis-style-content-left">395.</div><div class="two-column-analysis-style-content-right">Loan repayment program.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Applicability of certain provisions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- field-end:miscellaneous-note -->
<!-- field-end:notes -->
<!-- field-start:secref -->
<h4 class="note-head">Chapter Referred to in Other Sections</h4>
<!-- field-end:secref -->
<!-- field-start:sectionreferredto -->
<p class="note-body">This chapter is referred to in sections 453, 457, 466, 467, 467f, 601, 607, 620, 679, 802, 811, 829, 902, 1033, 1049, 1052, 1401, 1402, 1403 of this title; title 7 sections 136v, 138i, 1431c, 5341, 6519; title 15 sections 70j, 1261, 1263, 1277, 1457, 1459, 1460, 2057a, 2057b, 2079; title 18 section 42; title 19 section 2578a; title 26 sections 170, 4817; title 35 sections 155, 156, 271; title 42 sections 262, 300aa&ndash;22, 300aa&ndash;23, 1396r&ndash;8, 1786, 3512, 7671.</p>
<!-- field-end:sectionreferredto -->


</body></html>